Columbia University Medical Center’s Clinical Trials Office, opened in 1992, is one of the first and most successful of its kind in the United States. It has pioneered a pattern of operation and service emulated by many other institutions here and abroad.

As our Clinical Trials Office celebrates this year its 10th anniversary of service to health care professionals and patients, it continues its broad mission to further promote the excellence, scope, and efficiency of clinical research activities at the Columbia University Health Sciences Division, the New York Presbyterian Hospital, and the New York Presbyterian Healthcare Network.

Bridging institutional lines, our Clinical Trials Office represents all of our several dozen networked institutions and is the only administrative unit that a clinical trial Sponsor needs to interface with when exploring the potentials for clinical trial placement and when negotiating a Clinical Trial Agreement.

We have forged an extensive network of affiliated hospitals, community-based ambulatory care sites, and single- and multi-specialty physician practice groups. Our Network has an unexcelled richness and depth of resources, comprising several thousand physicians ranging from academic physician "thought leaders" to community doctors with large practices.

An important outgrowth of this system has been our Clinical Trials Network (CTN) - a cooperative program that links sponsors and investigators with academic physicians, clinicians and a large diversity of patient populations, ethnic backgrounds, and patient care settings. Our CTN is an innovative clinical trials organization formed by Columbia University, Cornell University and the New York Presbyterian Hospital. It features superior centralized administration by our Clinical Trials Office, is overseen by highly experienced clinical researchers, and encompasses the exceptional facilities, resources, and intellectual capabilities of our academic medical centers and affiliated health care facilities and practices spread across the tri-state New York, New Jersey and Connecticut area.

Our CTN is organized around several therapeutically-focused groups: Cardiovascular, Diabetes mellitus, Liver and GI diseases, Neurology, Oncology, Primary Care, and Pediatrics.

To learn more about our Clinical Trials Office, its Clinical Trials Network, and the expertise and resources we offer, please visit the homepage of Columbia University Medical Center Clinical Trials Office. At that site, physicians, patients and clinical trial sponsors can also view a listing of the several hundred clinical trials now ongoing within our institutions.

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from Columbia University Medical Center will then follow-up with you.

CenterWatch is listing the following trials that are actively recruiting patients at this center.

• A multi-center, open-labeled study of the safety, efficacy, and pharmacokinetics of lupiprostone in pediatric patients with constipation.
• An fMRI Study of Self-Regulation in Adolescents with Bulimia Nervosa (Bn)
• Clinical Study of Spinal Muscular Atrophy Condition
• Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Newly Diagnosed Multiple Myeloma.
• Energy Homeostasis in Human Obesity and Effects of Low-Dose Leptin on the Metabolic/Behavioral Phenotypes of the Formerly Obese
• Multi-center Phase II Combination Therapy Selection Trial In ALS
• Multi-center Phase II Combination Therapy Selection Trials in ALS
• Multicenter Genetic Study of Rolandic Epilepsy
• Myeloma Specimen Repository Protocol, Ancillary.
• Obesity Study
• Peripheral Blood Stem Cell Mobilization and Storage in Patients with Chronic Myelogenous Leukemia in Complete Cytogenetic Remission on Imatinib.
• Phase I Study of CellCept (Mycophenolate Mofetil) for Advanced Pancreatic Cancer Phase
• Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/ Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
• Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
• Research on ADHD and Smoking
• Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients with Epidermolysis Bullosa (EB)
• This is a phase II study in which patients will receive uniform doses of fludarabine and rituximab for low-grade lymphoma and chronic lymphocytic leukemia, and for responding patients who can tolerate it, CAMPATH will be given only during the final 2 months of treatment on this study.
• This study involves the injection of certain peptides and an immune system stimulating substance to try to stimulate the immune system to recognize and kill melanoma tumor cells.
• This study involves the injection of certain peptides and an immune system stimulating substance to try to stimulate the immune system to recognize and kill tumor cells.
• Vascular Endothelial Growth Factor for Treatment of Diabetic Neuropathy
• VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)

For more information, please contact:

Eileen Enny Leach MPH, RN
Columbia University Medical Center
Clinical Trials Office
622 West 168th St.
PH 15 Center
New York, NY 10032 USA
Phone: 212-305-5063
Fax: 212-305-5065
E-mail:

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.

Name:
Address:
City:
State:
Zip:
Phone:
Email address:
Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

Last updated on February 25, 2008

PAC>